Comprehensive Analysis of CXCL6 Biological Significance in Head and Neck Squamous Cell Carcinoma

© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

This study investigates the role of CXCL6 in head and neck squamous carcinoma (HNSC) through comprehensive expression and methylation analyses, genetic mutation analysis, and prognostic assessment. Utilizing the UALCAN dataset, CXCL6 expression analysis revealed a significant overexpression in HNSC cells compared to normal control samples, indicating its role in HNSC proliferation. Furthermore, an analysis of CXCL6 expression across different clinical parameters showed substantial up-regulation in various cancer stages, racial groups, gender, and age groups, underscoring its fundamental role in cancer progression. Validation of CXCL6 expression using the GEPIA2.0 online tool confirmed that CXCL6 was highly expressed in HNSC development compared to control samples. An analysis of CXCL6 expression across different stages of cancer revealed dysregulation in all four stages, with the highest expression in stage II and the lowest in stage III. This study also explored the promoter methylation levels of CXCL6, establishing a significant association between HNSC samples and normal controls. Examining promoter methylation across different clinical parameters revealed considerable variations, with distinct methylation patterns observed across cancer stages, racial groups, gender, and age. Overall survival (OS) and disease-free survival (DFS) analyses using the KM plotter tool demonstrated that high CXCL6 expression was associated with poorer OS compared to low expression levels. Similarly, DFS analysis showed that patients with low CXCL6 expression experienced better DFS outcomes compared to those with high CXCL6 expression. Finally, mutational analysis using cBioPortal revealed no significant mutations in HNSC samples. These findings highlight the complex involvement of CXCL6 in HNSC pathogenesis, underscoring its potential as a prognostic biomarker and therapeutic target in HNSC management.

References

Gupta B, Johnson NW, Kumar N, 2016, Global Epidemiology of Head and Neck Cancers: A Continuing Challenge. Oncology, 91(1): 13–23. https://doi.org/10.1159/000446117

Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68(6): 394–424. https://doi.org/10.3322/caac.21492. Erratum in CA Cancer J Clin, 70(4): 313. https://doi.org/10.3322/caac.21609

Siegel RL, Miller KD, Jemal A, 2018, Cancer Statistics, 2018. CA Cancer J Clin, 68(1): 7–30. https://doi.org/10.3322/caac.21442

Wyss A, Hashibe M, Chuang SC, et al., 2013, Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol, 178(5): 679–690. https://doi.org/10.1093/aje/kwt029

Sturgis EM, Cinciripini PM, 2007, Trends in Head and Neck Cancer Incidence in Relation to Smoking Prevalence: An Emerging Epidemic of Human Papillomavirus-Associated Cancers? Cancer, 110(7): 1429–1435. https://doi.org/10.1002/cncr.22963

Gillison ML, D'Souza G, Westra W, et al., 2008, Distinct Risk Factor Profiles for Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Cancers. J Natl Cancer Inst, 100(6): 407–420. https://doi.org/10.1093/jnci/djn025

Chaturvedi AK, Engels EA, Pfeiffer RM, et al., 2011, Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. J Clin Oncol, 29(32): 4294–4301. https://doi.org/10.1200/JCO.2011.36.4596

D'Souza G, Kreimer AR, Viscidi R, et al., 2007, Case-Control Study of Human Papillomavirus and Oropharyngeal Cancer. N Engl J Med, 356(19): 1944–1956. https://doi.org/10.1056/NEJMoa065497

Colevas AD, Yom SS, Pfister DG, et al., 2018, NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw, 16(5): 479–490. https://doi.org/10.6004/jnccn.2018.0026

Mourad M, Jetmore T, Jategaonkar AA, et al., 2017, Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study. J Oral Maxillofac Surg, 75(12): 2562–2572. https://doi.org/10.1016/j.joms.2017.05.008

Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, et al., 2017, Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol, 3(4): 524–548. https://doi.org/10.1001/jamaoncol.2016.5688. Erratum in JAMA Oncol, 3(3): 418. https://doi.org/10.1001/jamaoncol.2017.0098

Blomberg M, Nielsen A, Munk C, et al., 2011, Trends in Head and Neck Cancer Incidence in Denmark, 1978–2007: Focus on Human Papillomavirus Associated Sites. Int J Cancer, 129(3): 733–741. https://doi.org/10.1002/ijc.25699

Buttmann-Schweiger N, Delere Y, Klug SJ, et al., 2017, Cancer Incidence in Germany Attributable to Human Papillomavirus in 2013. BMC Cancer, 17(1): 682. https://doi.org/10.1186/s12885-017-3678-6

Hansen BT, Campbell S, Nygard M, 2018, Long-Term Incidence Trends of HPV-Related Cancers, and Cases Preventable by HPV Vaccination: A Registry-Based Study in Norway. BMJ Open, 8(2): e019005. https://doi.org/10.1136/bmjopen-2017-019005

Henneman R, Van Monsjou HS, Verhagen CV, et al., 2015, Incidence Changes of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma and Effects on Survival in the Netherlands Cancer Institute, 1980–2009. Anticancer Res, 35(7): 4015–4022.

Hocking JS, Stein A, Conway EL, et al., 2011, Head and Neck Cancer in Australia between 1982 and 2005 Show Increasing Incidence of Potentially HPV-Associated Oropharyngeal Cancers. Br J Cancer, 104(5): 886–891. https://doi.org/10.1038/sj.bjc.6606091

Hwang TZ, Hsiao JR, Tsai CR, et al., 2015, Incidence Trends of Human Papillomavirus-Related Head and Neck Cancer in Taiwan, 1995–2009. Int J Cancer, 137(2): 395–408. https://doi.org/10.1002/ijc.29330

Mahal BA, Catalano PJ, Haddad RI, et al., 2019, Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev, 28(10): 1660–1667. https://doi.org/10.1158/1055-9965.EPI-19-0038

Duprez F, Berwouts D, De Neve W, et al., 2017, Distant Metastases in Head and Neck Cancer. Head Neck, 39(9): 1733–1743. https://doi.org/10.1002/hed.24687

Leeman JE, Li JG, Pei X, et al., 2017, Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. JAMA Oncol, 3(11): 1487–1494. https://doi.org/10.1001/jamaoncol.2017.0973

Chai RC, Lambie D, Verma M, et al., 2015, Current Trends in the Etiology and Diagnosis of HPV-Related Head and Neck Cancers. Cancer Med, 4(4): 596–607. https://doi.org/10.1002/cam4.424

Leemans CR, Snijders PJF, Brakenhoff RH, 2018, The Molecular Landscape of Head and Neck Cancer. Nat Rev Cancer, 18(5): 269–282. https://doi.org/10.1038/nrc.2018.11. Erratum in Nat Rev Cancer, 18(10): 662. https://doi.org/10.1038/s41568-018-0057-9

Bellairs JA, Hasina R, Agrawal N, 2017, Tumor DNA: An Emerging Biomarker in Head and Neck Cancer. Cancer Metastasis Rev, 36(3): 515–523. https://doi.org/10.1007/s10555-017-9685-x

Vokes EE, Agrawal N, Seiwert TY, 2015, HPV-Associated Head and Neck Cancer. J Natl Cancer Inst, 107(12): djv344. https://doi.org/10.1093/jnci/djv344

Proost P, De Wolf-Peeters C, Conings R, et al., 1993, Identification of A Novel Granulocyte Chemotactic Protein (GCP-2) from Human Tumor Cells. In Vitro and In Vivo Comparison with Natural Forms of GRO, IP-10, and IL-8. J Immunol, 150(3): 1000–1010.

Wasmuth HE, Lammert F, Zaldivar MM, et al., 2009, Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. Gastroenterology, 137(1): 309–319, 319.e1–3. https://doi.org/10.1053/j.gastro.2009.03.053

Sadik CD, Kim ND, Luster AD, Neutrophils Cascading Their Way to Inflammation. Trends Immunol, 32(10): 452–460. https://doi.org/10.1016/j.it.2011.06.008

Balamayooran G, Batra S, Cai S, et al., 2012, Role of CXCL5 in Leukocyte Recruitment to the Lungs During Secondhand Smoke Exposure. Am J Respir Cell Mol Biol, 47(1): 104–111. https://doi.org/10.1165/rcmb.2011-0260OC

Kebschull M, Demmer R, Behle JH, et al., 2009, Granulocyte Chemotactic Protein 2 (gcp-2/cxcl6) Complements Interleukin-8 in Periodontal Disease. J Periodontal Res, 44(4): 465–471. https://doi.org/10.1111/j.1600-0765.2008.01134.x

Li Y, Flores R, Yu A, et al., 2011, Elevated Expression of CXC Chemokines in Pediatric Osteosarcoma Patients. Cancer, 117(1): 207–217. https://doi.org/10.1002/cncr.25563

Li J, Tang Z, Wang H, et al., 2018, CXCL6 Promotes Non-Small Cell Lung Cancer Cell Survival and Metastasis via Down-Regulation of miR-515-5p. Biomed Pharmacother, 97: 1182–1188. https://doi.org/10.1016/j.biopha.2017.11.004

Verbeke H, Struyf S, Berghmans N, et al., 2011, Isotypic Neutralizing Antibodies Against Mouse GCP-2/CXCL6 Inhibit Melanoma Growth and Metastasis. Cancer Lett, 302(1): 54–62. https://doi.org/10.1016/j.canlet.2010.12.013

Ma JC, Sun XW, Su H, et al., 2017, Fibroblast-Derived CXCL12/SDF-1alpha Promotes CXCL6 Secretion and Co-Operatively Enhances Metastatic Potential Through the PI3K/Akt/mTOR Pathway in Colon Cancer. World J Gastroenterol, 23(28): 5167–5178. https://doi.org/10.3748/wjg.v23.i28.5167

Maciejczyk A, Szelachowska J, Czapiga B, et al., 2013, Elevated BUBR1 Expression is Associated with Poor Survival in Early Breast Cancer Patients: 15-Year Follow-Up Analysis. J Histochem Cytochem, 61(5): 330–339. https://doi.org/10.1369/0022155413480148

Chandrashekar DS, Bashel B, Balasubramanya SAH, et al., 2017, UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8): 649–658. https://doi.org/10.1016/j.neo.2017.05.002

Tang Z, Kang B, Li C, et al., 2019, GEPIA2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Res, 47(W1): W556–W560. https://doi.org/10.1093/nar/gkz430

Cerami E, Gao J, Dogrusoz U, et al., 2012, The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov, 2(5): 401–404. https://doi.org/10.1158/2159-8290.CD-12-0095. Erratum in Cancer Discov, 2(10): 960.

Pfister DG, Spencer S, Brizel DM, et al., 2014, Head and Neck Cancers, Version 2.2014. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 12(10): 1454–1487. https://doi.org/10.6004/jnccn.2014.0142

Argiris A, Karamouzis MV, Raben D, et al., 2008, Head and Neck Cancer. Lancet, 371(9625): 1695–1709. https://doi.org/10.1016/S0140-6736(08)60728-X

Pignon JP, le Maitre A, Maillard E, et al., 2009, Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomised Trials and 17,346 Patients. Radiother Oncol, 92(1): 4–14. https://doi.org/10.1016/j.radonc.2009.04.014

Lacas B, Carmel A, Landais C, et al., 2021, Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 107 Randomized Trials and 19,805 Patients, on Behalf of MACH-NC Group. Radiother Oncol, 156: 281–293. https://doi.org/10.1016/j.radonc.2021.01.013

Adelstein DJ, Li Y, Adams GL, et al., 2003, An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients with Unresectable Squamous Cell Head and Neck Cancer. J Clin Oncol, 21(1): 92–98. https://doi.org/10.1200/JCO.2003.01.008

Marta GN, Riera R, Bossi P, et al., 2015, Induction Chemotherapy Prior to Surgery With or Without Postoperative Radiotherapy for Oral Cavity Cancer Patients: Systematic Review and Meta-Analysis. Eur J Cancer, 51(17): 2596–2603. https://doi.org/10.1016/j.ejca.2015.08.007

Bossi P, Lo Vullo S, Guzzo M, et al., 2014, Preoperative Chemotherapy in Advanced Resectable OCSCC: Long-Term Results of A Randomized Phase III Trial. Ann Oncol, 25(2): 462–466. https://doi.org/10.1093/annonc/mdt555

Chen AM, Felix C, Wang PC, et al., 2017, Reduced-Dose Radiotherapy for Human Papillomavirus-Associated Squamous-Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study. Lancet Oncol, 18(6): 803–811. https://doi.org/10.1016/S1470-2045(17)30246-2

Besnard AG, Struyf S, Guabiraba R, et al., 2013, CXCL6 Antibody Neutralization Prevents Lung Inflammation and Fibrosis in Mice in the Bleomycin Model. J Leukoc Biol, 94(6): 1317–1323. https://doi.org/10.1189/jlb.0313140

Rot A, von Andrian UH, 2004, Chemokines in Innate and Adaptive Host Defense: Basic Chemokinese Grammar for Immune Cells. Annu Rev Immunol, 22: 891–928. https://doi.org/10.1146/annurev.immunol.22.012703.104543

Xin H, Cao Y, Shao ML, et al., 2018, Chemokine CXCL3 Mediates Prostate Cancer Cells Proliferation, Migration and Gene Expression Changes in an Autocrine/Paracrine Fashion. Int Urol Nephrol, 50(5): 861–868. https://doi.org/10.1007/s11255-018-1818-9

Zhao J, Ou B, Han D, et al., 2017, Tumor-Derived CXCL5 Promotes Human Colorectal Cancer Metastasis Through Activation of the ERK/Elk-1/Snail and AKT/GSK3beta/Beta-Catenin Pathways. Mol Cancer, 16(1): 70. https://doi.org/10.1186/s12943-017-0629-4

Le A, Lane AN, Hamaker M, et al., 2012, Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. Cell Metab, 15(1): 110–121. https://doi.org/10.1016/j.cmet.2011.12.009

Gijsbers K, Gouwy M, Struyf S, et al., 2005, GCP-2/CXCL6 Synergizes with Other Endothelial Cell-Derived Chemokines in Neutrophil Mobilization and is Associated with Angiogenesis in Gastrointestinal Tumors. Exp Cell Res, 303(2): 331–342. https://doi.org/10.1016/j.yexcr.2004.09.027

Engl T, Relja B, Blumenberg C, et al., 2006, Prostate Tumor CXC-Chemokine Profile Correlates with Cell Adhesion to Endothelium and Extracellular Matrix. Life Sci, 78(16): 1784–1793. https://doi.org/10.1016/j.lfs.2005.08.019

Zhu YM, Bagstaff SM, Woll PJ, 2006, Production and Upregulation of Granulocyte Chemotactic Protein-2/CXCL6 by IL-1beta and Hypoxia in Small Cell Lung Cancer. Br J Cancer, 94(12): 1936–41. https://doi.org/10.1038/sj.bjc.6603177

Van Coillie E, Van Aelst I, Wuyts A, et al., 2001, Tumor Angiogenesis Induced by Granulocyte Chemotactic Protein-2 as a Countercurrent Principle. Am J Pathol, 159(4): 1405–1414. https://doi.org/10.1016/S0002-9440(10)62527-8

Tian H, Huang P, Zhao Z, et al., 2014, HIF-1alpha Plays a Role in the Chemotactic Migration of Hepatocarcinoma Cells Through the Modulation of CXCL6 Expression. Cell Physiol Biochem, 34(5): 1536–1546. https://doi.org/10.1159/000366357

Wang J, Lu Y, Wang J, et al., 2008, CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway. Cancer Res, 68(24): 10367–10376. https://doi.org/10.1158/0008-5472.CAN-08-2780. Retraction in Cancer Res, 82(18): 3406. https://doi.org/10.1158/0008-5472.CAN-22-2399

Gao Q, Zhao YJ, Wang XY, et al., 2012, CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment that Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma. Cancer Res, 72(14): 3546–3556. https://doi.org/10.1158/0008-5472.CAN-11-4032

Guo L, Cui ZM, Zhang J, et al., 2011, Chemokine Axes CXCL12/CXCR4 and CXCL16/CXCR6 Correlate with Lymph Node Metastasis in Epithelial Ovarian Carcinoma. Chin J Cancer, 30(5): 336–43. https://doi.org/10.5732/cjc.010.10490

Previous article in this issue

Next article in this issue